Jubilant Pharmova Limited (JUBLPHARMA) - Net Assets

Latest as of September 2025: Rs65.72 Billion INR ≈ $710.70 Million USD

Based on the latest financial reports, Jubilant Pharmova Limited (JUBLPHARMA) has net assets worth Rs65.72 Billion INR (≈ $710.70 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs135.21 Billion ≈ $1.46 Billion USD) and total liabilities (Rs69.50 Billion ≈ $751.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Jubilant Pharmova Limited to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs65.72 Billion
% of Total Assets	48.6%
Annual Growth Rate	17.53%
5-Year Change	31.57%
10-Year Change	114.42%
Growth Volatility	34.31

Jubilant Pharmova Limited - Net Assets Trend (2004–2025)

This chart illustrates how Jubilant Pharmova Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see JUBLPHARMA company net worth.

Annual Net Assets for Jubilant Pharmova Limited (2004–2025)

The table below shows the annual net assets of Jubilant Pharmova Limited from 2004 to 2025. Also explore JUBLPHARMA year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-03-31	Rs62.39 Billion ≈ $674.68 Million	+15.08%
2024-03-31	Rs54.21 Billion ≈ $586.27 Million	+0.54%
2023-03-31	Rs53.92 Billion ≈ $583.10 Million	+1.42%
2022-03-31	Rs53.16 Billion ≈ $574.95 Million	+12.12%
2021-03-31	Rs47.42 Billion ≈ $512.78 Million	-15.39%
2020-03-31	Rs56.04 Billion ≈ $606.04 Million	+16.53%
2019-03-31	Rs48.09 Billion ≈ $520.08 Million	+19.18%
2018-03-31	Rs40.35 Billion ≈ $436.37 Million	+18.79%
2017-03-31	Rs33.97 Billion ≈ $367.35 Million	+16.74%
2016-03-31	Rs29.10 Billion ≈ $314.66 Million	+18.59%
2015-03-31	Rs24.54 Billion ≈ $265.34 Million	-11.89%
2014-03-31	Rs27.84 Billion ≈ $301.13 Million	+6.85%
2013-03-31	Rs26.06 Billion ≈ $281.82 Million	+8.64%
2012-03-31	Rs23.99 Billion ≈ $259.41 Million	+8.34%
2011-03-31	Rs22.14 Billion ≈ $239.44 Million	-1.12%
2010-03-31	Rs22.39 Billion ≈ $242.17 Million	+76.66%
2009-03-31	Rs12.68 Billion ≈ $137.08 Million	+0.90%
2008-03-31	Rs12.56 Billion ≈ $135.85 Million	+38.63%
2007-03-31	Rs9.06 Billion ≈ $98.00 Million	+7.77%
2006-03-31	Rs8.41 Billion ≈ $90.93 Million	+66.66%
2005-03-31	Rs5.04 Billion ≈ $54.56 Million	+140.46%
2004-03-31	Rs2.10 Billion ≈ $22.69 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jubilant Pharmova Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 4957.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs53.02 Billion	84.76%
Common Stock	Rs158.00 Million	0.25%
Other Comprehensive Income	Rs9.37 Billion	14.99%
Total Equity	Rs62.55 Billion	100.00%

Jubilant Pharmova Limited Competitors by Market Cap

The table below lists competitors of Jubilant Pharmova Limited ranked by their market capitalization.

Company	Market Cap
Douglas Emmett Inc NYSE:DEI	$1.73 Billion
Dunelm Group plc F:DFQ	$1.73 Billion
SRH Total Return Fund Inc. NYSE:STEW	$1.73 Billion
Shanghai Jahwa United Co Ltd SHG:600315	$1.73 Billion
Jeudan CO:JDAN	$1.73 Billion
Indo Tambangraya Megah Tbk JK:ITMG	$1.73 Billion
Xiamen ITG Group Corp Ltd SHG:600755	$1.73 Billion
Telecom Argentina S.A F:TEO	$1.73 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jubilant Pharmova Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 54,339,000,000 to 62,549,000,000, a change of 8,210,000,000 (15.1%).
Net income of 8,394,000,000 contributed positively to equity growth.
Dividend payments of 796,000,000 reduced retained earnings.
Share repurchases of 56,000,000 reduced equity.
New share issuances of 9,000,000 increased equity.
Other comprehensive income increased equity by 589,000,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs8.39 Billion	+13.42%
Dividends Paid	Rs796.00 Million	-1.27%
Share Repurchases	Rs56.00 Million	-0.09%
Share Issuances	Rs9.00 Million	+0.01%
Other Comprehensive Income	Rs589.00 Million	+0.94%
Other Changes	Rs70.00 Million	+0.11%
Total Change	Rs-	15.11%

Book Value vs Market Value Analysis

This analysis compares Jubilant Pharmova Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.57x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 78.21x to 2.57x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-03-31	Rs12.94	Rs1011.95	x
2005-03-31	Rs31.39	Rs1011.95	x
2006-03-31	Rs51.89	Rs1011.95	x
2007-03-31	Rs55.85	Rs1011.95	x
2008-03-31	Rs77.60	Rs1011.95	x
2009-03-31	Rs77.65	Rs1011.95	x
2010-03-31	Rs138.34	Rs1011.95	x
2011-03-31	Rs136.51	Rs1011.95	x
2012-03-31	Rs146.27	Rs1011.95	x
2013-03-31	Rs156.60	Rs1011.95	x
2014-03-31	Rs164.90	Rs1011.95	x
2015-03-31	Rs154.04	Rs1011.95	x
2016-03-31	Rs186.24	Rs1011.95	x
2017-03-31	Rs220.32	Rs1011.95	x
2018-03-31	Rs262.22	Rs1011.95	x
2019-03-31	Rs308.53	Rs1011.95	x
2020-03-31	Rs351.83	Rs1011.95	x
2021-03-31	Rs297.71	Rs1011.95	x
2022-03-31	Rs334.14	Rs1011.95	x
2023-03-31	Rs339.26	Rs1011.95	x
2024-03-31	Rs342.06	Rs1011.95	x
2025-03-31	Rs393.71	Rs1011.95	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jubilant Pharmova Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 13.42%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 11.60%
• Asset Turnover: 0.57x
• Equity Multiplier: 2.04x
Recent ROE (13.42%) is below the historical average (13.80%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	38.00%	9.11%	0.99x	4.22x	Rs576.48 Million
2005	23.87%	10.19%	0.93x	2.53x	Rs692.49 Million
2006	15.70%	8.61%	0.73x	2.48x	Rs471.03 Million
2007	25.65%	12.60%	0.56x	3.65x	Rs1.39 Billion
2008	32.43%	16.09%	0.59x	3.41x	Rs2.77 Billion
2009	22.92%	8.05%	0.53x	5.34x	Rs1.60 Billion
2010	19.15%	11.15%	0.55x	3.10x	Rs2.01 Billion
2011	10.58%	6.69%	0.45x	3.48x	Rs124.92 Million
2012	0.62%	0.34%	0.55x	3.37x	Rs-2.18 Billion
2013	6.12%	2.96%	0.61x	3.38x	Rs-967.08 Million
2014	-2.20%	-0.99%	0.66x	3.37x	Rs-3.20 Billion
2015	-2.35%	-0.99%	0.67x	3.52x	Rs-3.03 Billion
2016	13.47%	6.82%	0.64x	3.08x	Rs1.01 Billion
2017	16.75%	9.82%	0.65x	2.63x	Rs2.32 Billion
2018	15.73%	8.55%	0.78x	2.35x	Rs2.34 Billion
2019	11.95%	6.31%	0.79x	2.38x	Rs935.64 Million
2020	16.03%	15.03%	0.48x	2.23x	Rs3.38 Billion
2021	17.63%	13.71%	0.68x	1.88x	Rs3.62 Billion
2022	7.78%	6.75%	0.61x	1.88x	Rs-1.18 Billion
2023	-1.13%	-0.97%	0.56x	2.07x	Rs-6.01 Billion
2024	1.42%	1.15%	0.58x	2.13x	Rs-4.66 Billion
2025	13.42%	11.60%	0.57x	2.04x	Rs2.14 Billion

Industry Comparison

This section compares Jubilant Pharmova Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $28,018,515,021
Average return on equity (ROE) among peers: 13.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jubilant Pharmova Limited (JUBLPHARMA)	Rs65.72 Billion	38.00%	1.06x	$1.73 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$354.09 Million	3.07%	2.25x	$30.30 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.00 Billion	13.75%	2.66x	$420.83 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$13.86 Billion	-0.01%	0.47x	$773.91 Million
Abbott India Limited (ABBOTINDIA)	$3.05 Billion	19.95%	0.50x	$6.00 Billion
Ajanta Pharma Limited (AJANTPHARM)	$25.99 Billion	18.00%	0.28x	$4.74 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$33.31 Billion	7.66%	0.64x	$1.27 Billion
Alkem Laboratories Limited (ALKEM)	$12.05 Billion	19.50%	0.29x	$6.67 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$964.67 Million	9.99%	0.49x	$153.02 Million
Alembic Pharmaceuticals Limited (APLLTD)	$50.67 Billion	22.63%	0.32x	$1.75 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$138.92 Billion	17.02%	0.90x	$10.33 Billion

About Jubilant Pharmova Limited

NSE:JUBLPHARMA India Drug Manufacturers - Specialty & Generic

Market Cap

$1.73 Billion

Rs160.28 Billion INR

Market Cap Rank

#6687 Global

#306 in India

Share Price

Rs1011.95

Change (1 day)

-1.29%

52-Week Range

Rs807.65 - Rs1181.20

All Time High

Rs1269.00